anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lovenox
Trial phase: Not Applicable
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: Recieved low molecular weight heparin (LMWH) as a "bridge" to warfarin
Eligibility criteria:
Inclusion Criteria:

Symptomatic acute deep venous thrombosis and/or pulmonary embolism confirmed by venous ultrasound and/or CT scan.
Pulmonary embolism patients with normal right ventricular size on chest CT scan.
Age greater than 18 years
Anticipated discharge within 72 hours of admission
Written informed consent

Exclusion Criteria:

Pregnancy or intend to become pregnant
Patients requiring ongoing hospitalization > 72 hours
Hypersensitivity to heparin, pork products or enoxaparin
Creatinine > 2.0 mg/dl
Recurrent DVT and/or PE with oral anticoagulation
Surgery or medical procedure planned during the study that may pose a significant bleeding risk
Prior history of heparin-induced thrombocytopenia
Inability to participate for follow up appointments and study visits
Life expectancy < 30 days

High risk of bleeding:

Active major bleeding within 30 days by GUSTO criteria
History of intracranial bleeding
Major surgery or trauma within 10 days
Head injury requiring hospitalization within 1 year
Intracranial tumor
Neurosurgery or non-cataract ophthalmologic surgery within 1 month
Thrombocytopenia
Intervention: Valsartan
Trial phase: Phase 3
ATC code: C09CA03 | C09DA03 | C09DB01 | C09DB08 | C09DX01 | C09DX02 | C09DX04 | C09DX05 | C10BX10
SMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 307
Group description: 1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
Eligibility criteria:
Inclusion Criteria:

Male or female outpatients >= 18 years and < 86 years
Patients with essential diastolic hypertension
At visit 1, the patient must have mean sitting diastolic blood pressure >= 95 mmHg and < 10 mmHg; patients treated with antihypertensive medication must have a mean sitting diastolic blood pressure < 100 mmHg
At visit 2, patients must have a mean sitting diastolic blood pressure of >= 95 mmHg and < 100 mmHg
At visit 3, patients must have a mean sitting diastolic blood pressure of >= 90 mmHg and < 110 mmHg

Exclusion Criteria:

Severe hypertension >= 180/110 mmHg
Known or suspected contraindications, including a history of allergy or hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical structures
Inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to Visit 2
History of hypertensive encephalopathy, cerebrovascular accident or transient ischemic attack, myocardial infarction or other types of revascularization
Malignant hypertension
All patients with Type I diabetes and those patients with Type 2 diabetes who are not well controlled based on the investigator's clinical judgment
Pregnant or nursing women
History of heart failure
Angina pectoris
Second or third degree heart block
Life threatening or symptomatic arrhythmias
Clinically significant valvular heart disease
Evidence of a secondary form of hypertension
Known or moderate malignant retinopathy
Evidence of hepatic disease
Evidence of renal impairment

Other protocol-defined exclusion criteria may apply.
Intervention: Valsartan
Trial phase: Phase 3
ATC code: C09CA03 | C09DA03 | C09DB01 | C09DB08 | C09DX01 | C09DX02 | C09DX04 | C09DX05 | C10BX10
SMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 303
Group description: 1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
Eligibility criteria:
Inclusion Criteria:

Male or female outpatients >= 18 years and < 86 years
Patients with essential diastolic hypertension
At visit 1, the patient must have mean sitting diastolic blood pressure >= 95 mmHg and < 10 mmHg; patients treated with antihypertensive medication must have a mean sitting diastolic blood pressure < 100 mmHg
At visit 2, patients must have a mean sitting diastolic blood pressure of >= 95 mmHg and < 100 mmHg
At visit 3, patients must have a mean sitting diastolic blood pressure of >= 90 mmHg and < 110 mmHg

Exclusion Criteria:

Severe hypertension >= 180/110 mmHg
Known or suspected contraindications, including a history of allergy or hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical structures
Inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to Visit 2
History of hypertensive encephalopathy, cerebrovascular accident or transient ischemic attack, myocardial infarction or other types of revascularization
Malignant hypertension
All patients with Type I diabetes and those patients with Type 2 diabetes who are not well controlled based on the investigator's clinical judgment
Pregnant or nursing women
History of heart failure
Angina pectoris
Second or third degree heart block
Life threatening or symptomatic arrhythmias
Clinically significant valvular heart disease
Evidence of a secondary form of hypertension
Known or moderate malignant retinopathy
Evidence of hepatic disease
Evidence of renal impairment

Other protocol-defined exclusion criteria may apply.
Intervention: Paricalcitol
Trial phase: Phase 3
ATC code: H05BX02
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)/C=C/[C@H](C)C(C)(C)O)[C@@]1(C)CCC/C2=C\C=C1C[C@@H](O)C[C@H](O)C1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level

Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of XLH rickets
Fasting serum calcium of 10.7 mg/dl or less
Fasting PTH greater than 40 nleq/ml and less than 120 nleq/ml in the mid-molecule PTH assay at screening (upper limit of normal is 25 nleq/ml)
Willing and able to participate in the trial
Taking stable dose of standard therapy for XLH rickets for at least 2 months prior to study entry
Concomitant therapy for XLH rickets will not be an exclusion criteria
Parent or guardian willing to provide informed consent, if applicable

Exclusion Criteria:

Concomitant kidney failure (estimated creatinine clearance less than 60 cc/min or serum creatinine greater than 1.5 mg/dl)
Serum 25-hydroxy vitamin D less than 20 ng/ml. Participants meeting this criterion will receive vitamin D3 supplementation for 3 months and then be rescreened.
Unable to comply with protocol and appropriate follow-up visits
Treatment with agents that may affect skeletal metabolism, such as glucocorticoids and anticonvulsants
Intervention: Modafinil
Trial phase: Phase 3
ATC code: N06BA07 | N06BA13
SMILES: NC(=O)CS(=O)C(c1ccccc1)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: 18 mg PO once daily for 4 weeks
Eligibility criteria:
Inclusion Criteria:

Patient diagnosed with a brain tumor, either primary or metastatic
Patient had prior radiation treatment to the brain
Patient is > or = 18 years of age
Patient has a Karnofsky performance status (KPS) performance of 70 at baseline
Patient is using acceptable birth control methods. Female participants (if of child bearing age and sexually active) and male participants (if sexually active with a partner of child-bearing potential) must use medically acceptable methods of birth control, including abstinence, birth control pills, diaphragm with spermicide, condom with foam or spermicide, vaginal spermicidal suppository or surgical sterilization.
Patient must speak and understand English or Spanish
Patient has reported cognitive decline and is being considered for stimulant therapy by their neurologist
Patient has provided written informed consent to participate in the study prior to enrollment to the study

Exclusion Criteria:

History of hypersensitivity reaction to methylphenidate or modafinil
History of severe headaches, glaucoma, major psychiatric diagnosis, narcolepsy, Tourette's syndrome, marked anxiety, tension or agitation
History of clinically significant pulmonary or cardiac disease
Uncontrolled hypertension: has not been on a stable treatment dose for the past month, or has a systolic pressure consistently greater than 140 mm Hg or diastolic pressure consistently greater than 90 mm Hg
Patients with uncontrolled seizures will be excluded
Current use of illicit drugs or history of alcohol or drug abuse and/or abuse potential
Moderate to severe depression (> 20 on Beck Depression Inventory II)
If taking antidepressants, patient must be on a stable dose
Currently taking psychostimulants, Monoamine oxidase (MAO) inhibitors, or anticoagulants
Current use of the following herbals or supplements for fatigue relief (dehydroepiandrosterone (DHEA), S-Adenosyl methionine (SAME), ginkgo, ginseng, St. John's Wort)
Any coexisting medical condition or are taking any concomitant medication that is likely to interfere with the safe administration of methylphenidate. Any potential interactions or coexisting medical condition not specified by the protocol will be determined by the prescribing physician as being exclusionary or not.
Patients currently taking any erythropoietin type drugs
Intervention: Amphotericin B
Trial phase: Phase 2
ATC code: A01AB04 | A07AA07 | G01AA03 | J02AA01
SMILES: CC1C=CC=CC=CC=CC=CC=CC=CC(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)CC(O)C(O)CCC(O)CC(O)CC(=O)OC(C)C(C)C1O)CC(O)C2C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: 3 mg/kg intravenously (IV) three times per week
Eligibility criteria:
Inclusion Criteria:

Diagnosis of AML or high risk MDS undergoing induction chemotherapy or first salvage chemotherapy.
Age >/=18 years.
Patients must sign an informed consent.

Exclusion Criteria:

Patients with history of anaphylaxis attributed to azole or amphotericin B compounds.
Patients with clinical or other evidence that indicates that they have proven or probable invasive fungal infection prior to enrollment.
Patients with total bilirubin levels > 3 times the upper normal limits (i.e. > 3.0 mg/dl); or serum glutamic pyruvic transaminase (SGPT)> 5 times upper limit normal.
Patients with serum creatinine > 2.0 mg/dl.
Patients receiving any medication that is contraindicated with the use of voriconazole.
Patients who have participated in this study during induction chemotherapy.
Intervention: Amphotericin B
Trial phase: Phase 2
ATC code: A01AB04 | A07AA07 | G01AA03 | J02AA01
SMILES: CC1C=CC=CC=CC=CC=CC=CC=CC(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)CC(O)C(O)CCC(O)CC(O)CC(=O)OC(C)C(C)C1O)CC(O)C2C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: 9 mg/kg IV once per week
Eligibility criteria:
Inclusion Criteria:

Diagnosis of AML or high risk MDS undergoing induction chemotherapy or first salvage chemotherapy.
Age >/=18 years.
Patients must sign an informed consent.

Exclusion Criteria:

Patients with history of anaphylaxis attributed to azole or amphotericin B compounds.
Patients with clinical or other evidence that indicates that they have proven or probable invasive fungal infection prior to enrollment.
Patients with total bilirubin levels > 3 times the upper normal limits (i.e. > 3.0 mg/dl); or serum glutamic pyruvic transaminase (SGPT)> 5 times upper limit normal.
Patients with serum creatinine > 2.0 mg/dl.
Patients receiving any medication that is contraindicated with the use of voriconazole.
Patients who have participated in this study during induction chemotherapy.
Intervention: Voriconazole
Trial phase: Phase 2
ATC code: J02AC03
SMILES: C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 40
Group description: 400 mg oral twice daily day 1 followed by 200 mg twice daily
Eligibility criteria:
Inclusion Criteria:

Diagnosis of AML or high risk MDS undergoing induction chemotherapy or first salvage chemotherapy.
Age >/=18 years.
Patients must sign an informed consent.

Exclusion Criteria:

Patients with history of anaphylaxis attributed to azole or amphotericin B compounds.
Patients with clinical or other evidence that indicates that they have proven or probable invasive fungal infection prior to enrollment.
Patients with total bilirubin levels > 3 times the upper normal limits (i.e. > 3.0 mg/dl); or serum glutamic pyruvic transaminase (SGPT)> 5 times upper limit normal.
Patients with serum creatinine > 2.0 mg/dl.
Patients receiving any medication that is contraindicated with the use of voriconazole.
Patients who have participated in this study during induction chemotherapy.
Intervention: Calcitriol
Trial phase: Phase 2
ATC code: A11CC04 | D05AX03
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)(C)O)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)C[C@H](O)C1=C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 25
Group description: Participants received calcitriol 3 micrograms per gram (mcg/g) ointment applied topically twice daily for 56 days.
Eligibility criteria:
Inclusion Criteria:

Diagnosis of chronic plaque psoriasis
10 - 35% BSA of involved skin
Age 12 - 17

Exclusion Criteria:

Other type of psoriasis (other than plaque)
Significant abnormal lab findings
Vit D insufficiency
Intervention: Humalog
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)NC(CCCCN)C(=O)N3CCCC3C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 114
Group description: Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Clinically diagnosed type 1or type 2 diabetes for at least 2 months
Aged between 18 and 70 (inclusive)
Have been treated with human insulin mix 30/70 twice daily for at least 2 months prior to entering the study
Have glycosylated hemoglobin (Hb1Ac) between 1.2 and 1.7 times the upper limit of normal reference range within 2 weeks prior to or at Visit 1
Compliance with diet and insulin therapy and performs regular blood glucose monitoring

Exclusion Criteria:

Have used oral antidiabetic agents within 30 days prior to entry into the study
Receive a total daily dose of insulin >2 units/kilogram
Have had more than two episodes of severe hypoglycemia within 6 months prior to entry into the study
Have a body mass index >35 kilograms per square meter (kg/m2)
Receive chronic systemic glucocorticoid therapy
Intervention: Bivalirudin
Trial phase: Phase 3
ATC code: B01AE06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Abatacept was administered IV on Day 1, 15, 29 and every 28 days up to and including Day 113.Abatacept was given as a dose based on body weight: 500 mg for participants weighing < 60 kg, 750 mg for participants weighing 60 to 100 kg and 1 gram for participants weighing > 100 kg. In addition, participants received a weekly dose of MTX of at least 15 mg or a maximum tolerated dose (ie, 10 mg weekly)
Eligibility criteria:
Inclusion Criteria:

Disease activity as defined by a Disease Activity Score 28-C-Reactive Protein (CRP) >3.2 or >6 swollen and ≥6 tender joints and CRP greater than the upper limit of normal
At least 1 erosion in hands/wrists or positive anticyclic citrullinated peptides or rheumatoid factor
Clinically detectable synovitis of at least 1 wrist/ankle at screening and baseline
Participants must have been treated with methotrexate, on a weekly dose of at least 15 mg or a maximum tolerated dose (such as, 10 mg weekly) for at least 3 months before screening. Dose of methotrexate must be stable for at least 28 days prior to the first study dose (Day 1)
Intervention: MK-0249
Trial phase: Phase 2
SMILES: Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 73
Group description: Patients were randomly assigned to 28 days of treatment with 5 mg MK-0249 taken orally daily (qd).
Eligibility criteria:
Inclusion Criteria:

Male or females
Age at least 55 years or older
Mild-to-moderate Alzheimer's Disease, with Mini Mental State Examination (MMSE) between 18 and 26, inclusive, Modified Hachinski Ischemic Scale (MHIS) score =/<4, Global CDR score of 1 or 2, and who have a reliable informant/caregiver to accompany patient to all clinic visits
If using symptomatic Alzheimer's Disease treatments, patients must be on the medication for 3 months and on a STABLE DOSE for at least 2 months

Exclusion Criteria:

Patients cannot be living in a skilled nursing facility
Patients cannot have poorly-controlled hypertension
Patients cannot have the following conditions within 6 months of screening: significant cardiovascular disorders, active major depressive disorder, gastroesophageal reflux disease (GERD), or clinically significant sleep disorder
Various concomitant therapy restrictions
Intervention: Ziprasidone
Trial phase: Phase 3
ATC code: N05AE04
SMILES: O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 8
Group description: Ziprasidone: subjects will use ziprasidone
Eligibility criteria:
Inclusion Criteria:

Children who meet DSM-IV criteria for the following psychotic disorders: schizophreniform disorder, schizoaffective disorder, psychosis NOS, major depressive disorder with psychotic features, and bipolar disorder with psychotic features.
Children with an IQ of at least 70.
Children who are in good physical health.
The parent/guardian of the child must be willing to attend all study visits.

Exclusion Criteria:

Children who are currently receiving an effective treatment without detrimental side effects.
Children who are allergic to Geodon®.
Children who have previously failed to respond to an adequate trial of Geodon®.
Females who are pregnant or breast-feeding.
Intervention: Adapalene
Trial phase: Phase 3
ATC code: D10AD03 | D10AD53
SMILES: COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 418
Group description: Adapalene Topical Gel
Eligibility criteria:
Inclusion Criteria:

A clinical diagnosis of acne vulgaris with facial involvement.
A minimum of 20 but not more than 50 Inflammatory lesions
A minimum of 30 but not more than 100 Noninflammatory lesions
A score of 3 (Moderate) on the Investigator's Global Assessment Scale.

Exclusion Criteria:

More than one acne nodule or any acne cyst.
Acne conglobata, acne fulminans, secondary acne, or severe acne.
Known previous participation in an Adapalene/Benzoyl Peroxide Topical Gel Trial.
Underlying diseases that require the use of interfering topical or systemic therapy.
Use of prohibited medications prior to the study unless appropriate washout period is documented
Use of hormonal contraceptives solely for control of acne
Intervention: BENZOYL PEROXIDE
Trial phase: Phase 3
ATC code: D10AE01 | D10AE51
SMILES: O=C(OOC(=O)c1ccccc1)c1ccccc1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 415
Group description: Benzoyl Peroxide Topical Gel
Eligibility criteria:
Inclusion Criteria:

A clinical diagnosis of acne vulgaris with facial involvement.
A minimum of 20 but not more than 50 Inflammatory lesions
A minimum of 30 but not more than 100 Noninflammatory lesions
A score of 3 (Moderate) on the Investigator's Global Assessment Scale.

Exclusion Criteria:

More than one acne nodule or any acne cyst.
Acne conglobata, acne fulminans, secondary acne, or severe acne.
Known previous participation in an Adapalene/Benzoyl Peroxide Topical Gel Trial.
Underlying diseases that require the use of interfering topical or systemic therapy.
Use of prohibited medications prior to the study unless appropriate washout period is documented
Use of hormonal contraceptives solely for control of acne
Intervention: Victoza
Trial phase: Phase 2
ATC code: A10BJ02
SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 95
Group description: Liraglutide 1.2 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
Eligibility criteria:
Inclusion Criteria:

Body Mass Index (BMI) greater than or equal to 30.0 or lesser than or equal to 40.0 kg/m2
Stable body weight (less than 5% selfreported change within the last 3 months)

Exclusion Criteria:

Obesity induced by drug treatment
Use of approved drugs for weight lowering intervention (e.g. orlistat, sibutramin, rimonabant) within the last 3 months prior to entering trial
Type 1 or type 2 diabetes
Intervention: Victoza
Trial phase: Phase 2
ATC code: A10BJ02
SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 90
Group description: Liraglutide 1.8 mg once daily, weeks 0-20 (double-blinded), extended to 52 weeks (sponsor was unblinded at 20 weeks). Subjects switched to receive liraglutide 2.4 mg once daily and then liraglutide 3.0 mg once daily in open-label extension period (weeks 52-104)
Eligibility criteria:
Inclusion Criteria:

Body Mass Index (BMI) greater than or equal to 30.0 or lesser than or equal to 40.0 kg/m2
Stable body weight (less than 5% selfreported change within the last 3 months)

Exclusion Criteria:

Obesity induced by drug treatment
Use of approved drugs for weight lowering intervention (e.g. orlistat, sibutramin, rimonabant) within the last 3 months prior to entering trial
Type 1 or type 2 diabetes